In the News
Alternative measures didn't help in conditions thought to affect accuracy of HbA1c level
Using fructosamine or glycated albumin did not improve overall accuracy of glycemic measurement in an African population overall or in patients with sickle cell trait, anemia, or renal impairment, according to a comparison of these measures with HbA1c level and continuous glucose monitoring.
Standard care noninferior to acellular, cellular matrix products for diabetic foot ulcers
Researchers found no clinically significant differences in ulcer healing between the treatment types but found that acellular matrix products were more cost-effective than cellular matrix products and should thus be considered if standard care fails.
Studies examine prescribing patterns, access issues with newer diabetes drug classes
Use of tirzepatide, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors increased sharply in the U.S. from 2021 to 2023, one study found, while another noted inequities in availability of newer medications for type 2 diabetes.
MKSAP quiz: Fasting hypoglycemia
This month's quiz asks readers to evaluate a 42-year-old man recently diagnosed with diabetes two weeks after a hospitalization for diabetic ketoacidosis.
Spotlight on diabetes prevention programs
Recent studies offered follow-up data and risk prediction tools from two long-standing programs to prevent progression from prediabetes to diabetes in the U.S. and the U.K.
Only 4 of 14 diabetes performance measures adequate, ACP position paper says
The College's Performance Measurement Committee recently reviewed 14 current performance measures for diabetes that are relevant to internal medicine.
Annals On Call: Expenditures after bariatric surgery
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode discussed the health expenditures of patients with diabetes who undergo bariatric surgery.
FDA issues statements on counterfeit, compounded semaglutide
The agency warned about a single lot of counterfeit semaglutide and announced that it would begin enforcing regulations against pharmacies and physicians compounding the drug now that the shortage is over.